STAND. COM. REP. NO.  131-20

 

Honolulu, Hawaii

                , 2020

 

RE:   H.B. No. 583

      H.D. 1

 

 

 

 

Honorable Scott K. Saiki

Speaker, House of Representatives

Thirtieth State Legislature

Regular Session of 2020

State of Hawaii

 

Sir:

 

     Your Committee on Health, to which was referred H.B. No. 583 entitled:

 

"A BILL FOR AN ACT RELATING TO CANNABIS FOR MEDICAL USE,"

 

begs leave to report as follows:

 

     The purpose of this measure is to:

 

     (1)  Legalize the manufacturing of edible cannabis products for medical purposes;

 

     (2)  Establish standards, including regulations and education protocols, for edible cannabis products;

 

     (3)  Require packaging to include a universal symbol, to be developed by the Department of Health, that identifies any product containing cannabis; and

 

     (4)  Require the Department to implement a cannabis product recall system.

 

Prior to the hearing on this measure, your Committee posted and made available for public review a proposed H.D. 1, which deletes the contents of the measure and inserts language that amends the medical cannabis dispensary law by:

 

     (1)  Making clarifying amendments related to the process for the voluntary or involuntary sale or transfer of a dispensary license; removing the exclusion from dispensary employment for certain convictions; and repealing certain restrictions on medical cannabis dispensary siting; and

 

     (2)  Including primary caregivers, qualifying out-of-state patients, and caregivers of a qualifying out-of-state patient as individuals able to access medical cannabis retail dispensing locations.

 

     Your Committee received testimony in support of the proposed H.D. 1 from the Department of Health, Hawaii Cannabis Industry Association, and one individual.  Your Committee received comments on the proposed H.D. 1 from Akamai Cannabis Clinic.

 

     Your Committee finds that this measure will make improvements to the State's medical cannabis dispensary law and help fulfill the original intent of the program by clarifying provisions and implementing reasonable modifications to support patient access to medical cannabis and manufactured cannabis products.

 

Your Committee has amended this measure by adopting the proposed H.D. 1 and further amending the measure by:

 

     (1)  Changing the effective date to July 1, 2050, to encourage further discussion; and

 

     (2)  Making technical, nonsubstantive amendments for the purposes of clarity, consistency, and style.

 

     As affirmed by the record of votes of the members of your Committee on Health that is attached to this report, your Committee is in accord with the intent and purpose of H.B. No. 583, as amended herein, and recommends that it pass Second Reading in the form attached hereto as H.B. No. 583, H.D. 1, and be referred to your Committees on Judiciary and Consumer Protection & Commerce.

 

 

Respectfully submitted on behalf of the members of the Committee on Health,

 

 

 

 

____________________________

JOHN M. MIZUNO, Chair